tldrdailynews.com logo

Eli Lilly to acquire CrossBridge Bio in a deal valued up to $300 million

1 min read
Source: Endpoints News
Eli Lilly to acquire CrossBridge Bio in a deal valued up to $300 million
Photo: Endpoints News
TL;DR Summary

Eli Lilly agreed to acquire Houston-based CrossBridge Bio, a startup focused on antibody-drug conjugates, in a deal worth up to $300 million, expanding Lilly's biotech and ADC capabilities.

Topics:business#acquisition#antibody-drug-conjugate#biotech-deal#business#crossbridge-bio#eli-lilly
Share this article
  1. Eli Lilly to acquire tiny Houston startup CrossBridge Bio for up to $300M  Endpoints News
  2. CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Generation Dual-Payload Antibody-Drug Conjugates  Business Wire
  3. Eli Lilly to buy Houston cancer-fighting startup CrossBridge Bio in $300M deal  The Business Journals
  4. CrossBridge sells early | ApexOnco - Clinical Trials news and analysis  Oncology Pipeline
  5. Lilly makes preclinical ADC specialist CrossBridge its latest acquisition in vague $300M deal  Fierce Biotech

Reading Insights

Total Reads

0

Unique Readers

16

Time Saved

0 min

vs 1 min read

Condensed

67%

85 → 28 words

Want the full story? Read the original article

Read on Endpoints News